Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Saved in:
Bibliographic Details
Published in:Leukemia 2022-03, Vol.36 (3), p.881-884
Main Authors: Bobin, Arthur, Kyheng, Maéva, Guidez, Stéphanie, Gruchet-Merouze, Cécile, Richez, Valentine, Duhamel, Alain, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean-Valère, Bourquard, Pascal, Lenain, Pascal, Perrot, Aurore, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Moreau, Philippe, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, Leleu, Xavier
Format: Article
Language:English
Subjects:
692/308/153
692/699/1541/1990/804
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Cancer Research
Critical Care Medicine
Hematology
Humans
Inhibitor drugs
Intensive
Internal Medicine
Letter
Leukemia
Life Sciences
Maintenance Chemotherapy
Medicine
Medicine & Public Health
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Oligopeptides - adverse effects
Oligopeptides - therapeutic use
Oncology
Progression-Free Survival
Survival analysis
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-021-01415-x